Zevra Therapeutics (ZVRA) EBIAT (2016 - 2025)
Historic EBIAT for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to -$544000.0.
- Zevra Therapeutics' EBIAT rose 9836.27% to -$544000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.3 million, marking a year-over-year increase of 13941.6%. This contributed to the annual value of -$105.5 million for FY2024, which is 12912.77% down from last year.
- Per Zevra Therapeutics' latest filing, its EBIAT stood at -$544000.0 for Q3 2025, which was up 9836.27% from $74.7 million recorded in Q2 2025.
- In the past 5 years, Zevra Therapeutics' EBIAT registered a high of $74.7 million during Q2 2025, and its lowest value of -$35.7 million during Q4 2024.
- Moreover, its 5-year median value for EBIAT was -$10.3 million (2021), whereas its average is -$5.6 million.
- Per our database at Business Quant, Zevra Therapeutics' EBIAT surged by 62211.87% in 2021 and then plummeted by 67438.79% in 2024.
- Over the past 5 years, Zevra Therapeutics' EBIAT (Quarter) stood at -$2.7 million in 2021, then skyrocketed by 312.73% to $5.8 million in 2022, then plummeted by 445.2% to -$19.8 million in 2023, then plummeted by 80.05% to -$35.7 million in 2024, then surged by 98.48% to -$544000.0 in 2025.
- Its EBIAT was -$544000.0 in Q3 2025, compared to $74.7 million in Q2 2025 and -$3.1 million in Q1 2025.